Member Statements:
Charles Grassley, IA
Max Baucus, MT

 

Witness Statements:

Panel I

Dr. David J. Graham, MPH, Associate Director for Science, Office of Drug Safety, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC

Panel II

Dr. Gurkirpal Singh, Adjunct Clinical Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA

Dr. Bruce M. Psaty, PhD, Professor, Medicine & Epidemiology, University of Washington, Cardiovascular Health Research Unit, Seattle, WA

Panel III

Dr. Sandra L. Kweder, Acting Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC

Panel IV

Mr. Raymond V. Gilmartin, Chairman, President & Chief Executive Officer, Merck & Co., Whitehouse Station, NJ